Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cadence Builds Case For Branded IV Acetaminophen; Can It Reduce Opioid Use?

Executive Summary

After rebounding from regulatory setbacks, Cadence Pharmaceuticals Inc. intravenous acetaminophen Ofirmev has been approved by FDA with a label many analysts praise as broad and positive.
Advertisement

Related Content

Opioid-Sparing Claims Should Meet High Bar, US FDA Panel Says
Mallinckrodt Vision For Growth Emphasizes Acthar, Ofirmev
Deals Of The Week: UCSF Catalyzes R&D Tech-Transfer Deals With Private Sector
Covidien Spin-Out Mallinckrodt Makes First Move With $1.3B Cadence Buy
Tamper-Resistance Could Allow New Opioid Formulations To Differentiate Themselves
FDA Panel Supports Lower Acetaminophen Dose But Spares Combo Products

Topics

Advertisement
UsernamePublicRestriction

Register

PS052796

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel